Health
...
The FDA’s refusal to review Moderna’s mRNA flu vaccine
This week on "The Readout LOUD," everything you need to know about the FDA's controversial decision to block the review of Moderna’s mRNA flu shot.
ANALYZE
🏥
Health
Health, medicine and wellness news: medical research, prevention, nutrition, health tips.
204articles
Health
...
STAT+: Trump administration is urged to use a federal law to authorize generic versions of GLP-1 drugs
Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.
ANALYZE
Health
...
STAT+: FDA’s rejection of Moderna threatens to stifle broader vaccine industry
Experts say the FDA "moved the goalposts" on Moderna, creating "a destructive precedent that will undermine the future of vaccine development" in the U.S.
ANALYZE
Health
...
4 Months Trapped in a Hospital for an Obsolete Way of Treating Their Disease
Health workers in developing countries know that isolating tuberculosis patients is an outdated and potentially harmful practice, but lack the resources to move away from it.
ANALYZE
Health
...
Senate Questions Health Care Firm for Profiting Off Program Meant for Poor
The program was meant to help hospitals provide for poor patients by offering drug savings. But critics say a Texas company has turned it into a big business, driving up costs for patients and insurers.
ANALYZE
Health
...
STAT+: The messaging war over Medicaid cuts
This is the web edition of STAT's D.C. Diagnosis newsletter.
ANALYZE
Health
...
Nurses and other NHS staff to get 3.3% pay rise
Unions angry, but government says it demonstrates its commitment to workforce.
ANALYZE
Health
...
STAT+: NIH redefines ‘clinical trials,’ dividing researchers
In a long-debated move, the NIH will no longer characterize basic experimental studies involving humans as clinical trials.
ANALYZE
Health
...
STAT+: A change at the top of Sanofi
And other biotech news brought to you by The Readout newsletter
ANALYZE
Health
...
STAT+: Pharmalittle: We’re reading about Sanofi replacing its CEO, MFN drug pricing opposed by conservatives, and more
And other pharma news from the Pharmalot campus via the Pharmalittle newsletter
ANALYZE
Health
...
STAT+: STAT Health Tech: Researchers take another look at Apple’s hypertension feature
In this edition of STAT Health Tech: Fundraises by Talkiatry, Big Health, and the accuracy of Apple Watch hypertension feature.
ANALYZE
Health
...
STAT+: Big Health raises funding as investors see glimmer of hope for digital therapeutics
Big Health raises $24 million as investors bet that digital therapeutics' time has finally arrived.
ANALYZE
Health
...
STAT+: Talkiatry raises $210 million, eyeing opportunity to use AI for engaging with patients
Talkiatry, a virtual psychiatry company, announced Thursday it raised $210 million as it looks to build on its insurance-covered services.
ANALYZE
Health
...
What happens when pregnant people discontinue antidepressants?
And other health news from the Morning Rounds newsletter
ANALYZE
Health
...
STAT+: BridgeBio drug for genetic cause of dwarfism succeeds in key study
BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal clinical trial.
ANALYZE
Health
...
NHS waiting list at lowest level in three years
Backlog drops below 7.3m for first time since 2023 in England, but concern over long A&E waits.
ANALYZE
Health
...
STAT+: The old Vinay Prasad never left. He just changed jobs
Prasad changed jobs but his conservative regulatory doctrine remains the same, particularly for cell and gene therapies. The approval bar is much higher now.
ANALYZE
Health
...
NHS tracker - are hospital waiting times improving near you?
Use our interactive tracker to see if treatment waits are getting better at your local hospital.
ANALYZE
Health
...
How to check whether you have bowel cancer
What are the main symptoms and causes of bowel cancer, and how can you reduce your risk of getting it?
ANALYZE
Health
...
TV, It’s Not Just for Humans Anymore
Videos aimed at pets are drawing millions of views. But who’s actually watching?
ANALYZE